Market Signal Briefing

The exchange has processed more volume than Coinbase in recent months, according to The Block's data.

Iris Coleman
Oct 25, 2025 17:24

UNI price prediction shows bullish momentum building with MACD histogram turning positive. Analysts forecast $6.43 short-term, $7.06 medium-term targets as Uniswap breaks key resistance.

UNI Price Prediction Summary
• UNI short-term target (1 week): $6.43 (+3.4% from current $6.22)
• Uniswap medium-term forecast (1 month): $7.06-$8.60 range (+13.5% to +38.3%)
• Key level to break for bullish continuation: $6.64 (SMA 20 resistance)
• Critical support if bearish: $5.15 (Bollinger Band lower boundary)

Recent Uniswap Price Predictions from Analysts
The latest UNI price prediction landscape reveals a cautiously optimistic consensus among analysts. Changelly's progressive forecasts show an upward trajectory from $5.99 on October 21st to $6.43 today, indicating growing bullish sentiment. This Uniswap forecast aligns with the current technical setup showing early signs of momentum reversal.

More ambitious predictions include PriceForecastBot's UNI price target of $12.40 for the medium term, representing nearly 100% upside potential. Meanwhile, PricePredictions.com projects an aggressive long-term target of $37.03, though this appears overly optimistic given current market conditions.

The analyst consensus suggests UNI is consolidating around the $6.00-$6.50 range before potentially breaking higher, with medium confidence levels across most predictions.

UNI Technical Analysis: Setting Up for Bullish Breakout
Current Uniswap technical analysis reveals several encouraging signals despite the token trading 48.75% below its 52-week high of $12.13. The MACD histogram has turned positive at 0.0525, indicating early bullish momentum after a prolonged bearish phase.

The RSI reading of 39.06 sits in neutral territory, providing room for upward movement without entering overbought conditions. This positioning is particularly constructive for sustained price appreciation.

UNI's current price of $6.22 sits near the Bollinger Band middle line ($6.64), with a %B position of 0.3581 suggesting the token has room to move toward the upper band at $8.14. The daily ATR of $0.59 indicates moderate volatility, which could support controlled upward movement.

Volume analysis shows $15.33 million in 24-hour trading on Binance, providing adequate liquidity for institutional participation. The key resistance cluster between $6.64 (SMA 20) and $6.89 (EMA 26) represents the critical breakout zone for confirming the bullish UNI price prediction.

Uniswap Price Targets: Bull and Bear Scenarios
Bullish Case for UNI
The primary UNI price target in a bullish scenario points to $7.06, supported by CoinGape's medium-term analysis. This represents a 13.5% upside and appears achievable given the current technical setup.

A stronger breakout above the SMA 20 at $6.64 could propel UNI toward the immediate resistance at $8.60, offering 38.3% upside. This level coincides with the upper Bollinger Band region and would require sustained volume and momentum.

For this bullish Uniswap forecast to materialize, UNI needs to:
- Break and hold above $6.64 (SMA 20) with volume confirmation
- Maintain RSI above 50 for sustained momentum
- See MACD line cross above the signal line for additional confirmation

Bearish Risk for Uniswap
Downside risks remain significant if UNI fails to break the resistance cluster. A rejection at $6.64 could send the token back toward the lower Bollinger Band at $5.15, representing 17.2% downside risk.

The critical support zone between $5.99-$6.02, identified in recent analyst predictions, serves as the near-term floor. A break below this level would invalidate the bullish thesis and potentially target the strong support at $2.00, though this extreme scenario seems unlikely given current market conditions.

Key bearish triggers include RSI dropping below 35, MACD histogram turning negative, and trading volume declining below recent averages.

Should You Buy UNI Now? Entry Strategy
Based on current Uniswap technical analysis, the question of whether to buy or sell UNI depends on risk tolerance and timeframe. The technical setup suggests a favorable risk-reward ratio for patient investors.

Aggressive Entry: Current levels around $6.22 offer immediate exposure to potential upside, with a stop-loss at $5.90 (4.5% risk) targeting $7.06 (13.5% reward).

Conservative Entry: Wait for a breakout above $6.64 with volume confirmation before entering, targeting $8.60 with a stop-loss at $6.30.

Dollar-Cost Averaging: Given the mixed signals, accumulating UNI in the $6.00-$6.50 range over several weeks could reduce timing risk while capturing potential upside.

Position sizing should remain conservative at 2-3% of portfolio allocation given the moderate confidence levels in current predictions.

UNI Price Prediction Conclusion
The UNI price prediction for the coming weeks favors a cautiously bullish outlook, with technical indicators suggesting potential for 15-40% upside over the next month. The MACD histogram turning positive and RSI in neutral territory provide the foundation for this Uniswap forecast.

Key indicators to monitor for confirmation include:
- Breaking above $6.64 resistance with volume
- RSI sustaining above 45
- MACD line crossing above signal line

The prediction timeline suggests movement within 1-2 weeks, with medium confidence given the current technical setup. Traders should watch for volume confirmation at key levels and be prepared to adjust positions if the bearish scenario unfolds with a break below $5.90 support.

Current market conditions support the analyst consensus of gradual appreciation, making UNI an interesting risk-adjusted opportunity for those seeking exposure to the DeFi sector's leading automated market maker protocol.

Image source: Shutterstock

uni price analysis
uni price prediction

The Bitcoin price action has been somewhat impressive in 2025, as the flagship cryptocurrency ascended from around $93,300 in early January to its current all-time-high price of $126,000 this month. While the digital asset saw a couple of resets along the way, it continued to put in new highs, reflecting the magnitude of confidence held by its long-term investors.

However, the recent correction seen this October seems to be shaking that confidence, raising questions about the sustainability of Bitcoin’s bull cycle, and if the long-feared bear market is imminent. However, recent on-chain data points to an interestingly brighter outlook than what is currently being experienced by market participants.

Some Relevant BTC On-Chain Levels
In an October 24 post on the X platform, pseudonymous on-chain analyst Arch Physicist highlighted what could be encouraging news for Bitcoin market participants.

The crypto pundit’s analysis was based on the Value Coin-Days Destroyed (VCDD) to Spent Output Profit Ratio (SOPR) metric, which measures the amount of coins that are moved on the blockchain in relation to the potential profits based on their movements. Essentially, this metric is used to locate price zones that can serve as support or resistance. 

Arch Physicist highlighted four important readings from the metric, thereafter explaining on the underlying functions of each of them.

The analyst noted:

‘Gamma + Epsilon’ is used to determine structural highs formed due to Long-Term Holder (LTH) profit-taking, with its current value being around $147,937; ‘Delta + Epsilon’ represents support formed by Short-Term Holder (STH) entry opportunities, currently valued at approximately $92,902. Epsilon, on its part, is used to represent potential price floors. 

LTH Support Holds As Bitcoin Puts In Highs 
Arch Physicist further explained that the metric’s functions are in tandem with Bitcoin’s historical price action. “Bitcoin’s price has broken above the structural high (Gamma + Epsilon) and reached ATHs near Beta during bull runs. It has also historically made ATLs very close to Epsilon,” the analyst said.

Interestingly, the Bitcoin price in this cycle has consistently traded within the support zones established by its LTHs, and the ones by its STHs. However, price seems to be heading towards the lower support zone, which, if breached, could signal the beginning of a bear market. On the other hand, the sustained integrity of the upper support could also be indicating that the bull run has not even started. 

As of this writing, the price of BTC stands at approximately $11,890, with no significant movement in the past 24 hours. 

The price of BTC on the daily timeframe | Source: BTCUSDT chart on TradingView
Featured image from iStock, chart from TradingView

SOL price drifted higher and neared the critical $200 resistance as Staking Solana ETF inflows continued to rise. 

Summary

Solana price has bounced back from its lowest level this month.
The staking Solana ETF is continuing to have robust inflows.
Its assets under management have jumped to over $400 million.

Solana (SOL) token jumped to $195 today, Oct. 25, up by 12% from its lowest point this month. Its market capitalization was over $105 billion.

Data compiled by ETF.com shows that the REX-Osprey Staking Solana ETF has only experienced outflows in one week since its inception in August this year. 

SSK ETF had net inflows of $24 million this week, up from $14.5 million in the previous week. This growth has brought its assets under management to over $400 million, making it one of the biggest altcoin ETFs on Wall Street. 

The continued inflows, especially during a crypto bear market, is a sign that American institutional investors are interested in altcoin ETFs. Some see them as viable liquid alternative assets.

Its growth is also a sign that the mainstream Solana ETFs filed by companies like VanEck, 21Shares, Grayscale, Fidelity, and Fidelity will have demand. JPMorgan analysts believe that these funds will attract over $6 billion in inflows in the first year.

The SSK ETF has an expense ratio of 0.75%, which is higher than the future Solana ETFs. However, its main benefit is that it distributes all its staking revenue to investors. 

Solana’s network is doing well in other areas. For example, the stablecoin supply has jumped by 14% in the last 30 days to $15.6 billion, while the adjusted transaction volume soared by 55% to $48 billion. 

Solana is also the second-biggest player in the decentralized exchange industry, with its top protocols handling over $140 billion in volume in the last 30 days. Ethereum protocols processed $148 billion in the same period.

SOL price technical analysis
SOL price chart | Source: crypto.news
The daily chart shows that the Solana price bottomed at $94.70 in April and then rebounded to a high of $252 on Sept. 8, only to plunge to $178 as trade tensions between the U.S. and China escalated. 

It remains above the ascending trendline connecting the lows in April, June, and October. Not only that, it has formed a small triple-bottom pattern, which often leads to a bullish breakout. 

Therefore, the most likely Solana price forecast is bullish, with the next target being the key resistance at $205, its highest point in July this year. A move above that level will signal further gains, potentially to the September high of $253. A drop below the ascending trendline will invalidate the bullish view.

Key Points:

FalconX transferred 1,030 BTC to an inactive whale address.The transaction is valued at approximately $114 million.No official comment from FalconX on this transaction.
On October 25, a dormant whale address received approximately $114 million in Bitcoin (1,030 BTC) from FalconX, per Onchain Lens data.

This substantial transfer underscores the potential for significant shifts in BTC market dynamics, reflecting broader implications for liquidity and institutional involvement.

FalconX Transfers $114M in BTC to Dormant Whale
This event underscores potential strategic trades or liquidity adjustments in the market. The recipient immediately deposited 100 BTC to Kraken, suggesting a possible plan to realize profits or stabilize holdings.

As no official statements from key figures at FalconX have been made, the transaction remains speculative. Community discussions and primary sources are silent on motives, leaving the financial impact solely within the BTC markets.

No official statements or quotes from FalconX leadership or other key industry figures have been located regarding the transfer of 1,030 BTC to a previously inactive whale address on October 25, 2025.
Bitcoin Market Stability Amid Whale Movements
Did you know? Large Bitcoin transfers by whales such as this often signal potential market volatility following periods of accumulation or dormancy.

Bitcoin, trading at $111,264.68, shows a market capitalization of $2.22 trillion. Dominating 59.11% of total market share, BTC’s trading volume fell by 44.66% over the past 24 hours. Price changes in the last 7 and 60 days registered 4.11% and 1.39% respectively, per CoinMarketCap.

Bitcoin(BTC), daily chart, screenshot on CoinMarketCap at 16:30 UTC on October 25, 2025. Source: CoinMarketCap

According to Coincu, these data signify a broader stability campaign amid Whale interaction and underscore potential minor price rallies. Historical analysis places such transfers within cycles of strategic gain realization, yet public commentary is sparse.

DISCLAIMER: The information on this website is provided as general market commentary and does not constitute investment advice. We encourage you to do your own research before investing.

James Ding
Oct 25, 2025 17:42

LTC price prediction points to $105-110 upside potential over next 3-4 weeks as technical indicators show bullish momentum despite current consolidation below $100.

Litecoin continues to trade in a critical zone around $96, presenting mixed signals that have divided analyst predictions. With current technical indicators showing early bullish momentum and the cryptocurrency positioned strategically within its Bollinger Bands, our comprehensive LTC price prediction analysis suggests potential upside in the coming weeks.

LTC Price Prediction Summary
• LTC short-term target (1 week): $102-105 (+6-9%)
• Litecoin medium-term forecast (1 month): $105-110 range

• Key level to break for bullish continuation: $100.61
• Critical support if bearish: $87.45

Recent Litecoin Price Predictions from Analysts
The latest analyst predictions reveal a notably divided sentiment in the Litecoin forecast landscape. AMB Crypto maintains consistent optimism with their LTC price prediction of $94.03, representing a modest upside from current levels. Their analysis has remained remarkably stable over the past three days, suggesting confidence in their technical methodology.

Coinbase presents the most bullish long-term perspective with a $122.76 LTC price target, projecting a 27.6% increase over five years. This Litecoin forecast aligns with broader institutional adoption trends and suggests sustainable growth potential.

However, CoinCodex introduces a contrarian view with a bearish LTC price prediction of $74.91, indicating potential downside risk of approximately 22%. This creates an interesting dynamic where short-term predictions range from -22% to +5%, highlighting the current technical uncertainty.

The consensus among predictions suggests most analysts expect LTC to remain range-bound between $87-$101 in the near term, with the current price of $96.37 sitting comfortably within this range.

LTC Technical Analysis: Setting Up for Bullish Breakout
Current technical indicators provide compelling evidence for a potential upward move in our Litecoin technical analysis. The MACD histogram reading of 0.2860 indicates bullish momentum is building, despite the overall MACD remaining negative at -4.4296. This divergence often precedes significant price moves.

The RSI at 43.65 sits in neutral territory, providing room for upward movement without reaching overbought conditions. This positioning is particularly favorable for sustained price appreciation, as LTC has space to rally before encountering momentum-based resistance.

Litecoin's position within the Bollinger Bands at 0.4217 indicates the price is closer to the lower band ($78.61) than the upper band ($120.73), suggesting potential for mean reversion toward the middle band at $99.67. The current setup resembles a classic squeeze pattern that often precedes volatility expansion.

Volume analysis shows healthy participation at $18.8 million on Binance, providing sufficient liquidity for significant price movements. The 24-hour trading range of $95.63-$97.04 demonstrates contained volatility, which historically precedes breakout moves in either direction.

Litecoin Price Targets: Bull and Bear Scenarios
Bullish Case for LTC
Our primary LTC price target focuses on the $105-110 range for several technical reasons. The immediate resistance at $100.61 represents the first significant hurdle, aligning with AMB Crypto's bullish range projections. Breaking this level would likely trigger momentum buying toward the SMA 50 at $107.61.

The bullish scenario requires LTC to reclaim the SMA 20 at $99.67, which would shift the short-term trend structure. Volume confirmation above 25 million daily would strengthen this move significantly. The ultimate bullish LTC price target sits at $120.73, representing the upper Bollinger Band and a 25% upside potential.

Key bullish catalysts include breaking above $100.61 with volume, RSI moving above 50, and MACD crossing into positive territory. These technical confirmations would validate the upward prediction and potentially accelerate price discovery toward higher targets.

Bearish Risk for Litecoin
The bearish scenario aligns with CoinCodex's $74.91 prediction and centers around the critical support level at $87.45. A break below this level would invalidate the current consolidation pattern and potentially trigger a move toward the lower Bollinger Band at $78.61.

Risk factors include failure to reclaim $99.67, RSI dropping below 40, and MACD histogram turning negative. The strong support at $52.71 represents the ultimate downside target, though such a move would require significant fundamental deterioration in market conditions.

Volume below 15 million during any decline would suggest lack of selling pressure and could limit downside potential. However, a confirmed break below $87.45 with volume would shift our Litecoin forecast to bearish for the medium term.

Should You Buy LTC Now? Entry Strategy
Based on our analysis, the current level presents a reasonable entry opportunity for those asking whether to buy or sell LTC. The optimal entry strategy involves scale-in purchases between $94-96, with the current price of $96.37 near the upper end of this range.

Conservative traders should wait for a pullback to $94.08 (SMA 7) or lower before initiating positions. Aggressive traders can enter current levels with tight stop-losses below $92, representing approximately 4.5% risk.

Position sizing should reflect the mixed analyst sentiment, with conservative allocation recommended until technical confirmation emerges. A break above $100.61 would justify increasing position size, while failure to hold $94.08 suggests reducing exposure.

The risk-reward profile favors buyers at current levels, with upside potential to $105-110 offering a 2:1 reward-to-risk ratio when properly managed with stop-losses below key support levels.

LTC Price Prediction Conclusion
Our comprehensive LTC price prediction points to upside potential toward $105-110 over the next 3-4 weeks, representing a medium confidence forecast. The technical setup favors bulls despite mixed analyst sentiment, with key indicators suggesting accumulation near current levels.

Critical levels to monitor include the $100.61 resistance for bullish confirmation and $87.45 support for bearish invalidation. The Litecoin forecast timeline suggests resolution of the current consolidation within 1-2 weeks, with direction determined by these key levels.

Traders should watch for MACD crossing above zero, RSI breaking above 50, and volume expansion above 25 million as confirmation signals. The current environment favors patient accumulation with defined risk management rather than aggressive speculation in either direction.

Image source: Shutterstock

ltc price analysis
ltc price prediction

Key NotesRumble introduces Bitcoin tipping, enabling direct BTC donations to content creators.The feature debuted at the Lugano PlanB Bitcoin conference in Switzerland.JP Morgan also announced BTC and ETH as acceptable loan collateral, signaling broader corporate crypto adoption.
Streaming platform Rumble has announced the launch of a Bitcoin tipping feature that allows users to donate directly to creators and influencers in BTC. The feature debuted at the Lugano PlanB event on Friday, a conference hosted annually in Switzerland that brings together  Bitcoin-focused world leaders, technologists, and entrepreneurs.

Rumble Unveils Bitcoin Tipping for Content Creators at Lugano PlanB
Canadian legal commentator and long-term Rumble user Viva Frei, became the first content creator to test the feature, using Rumble’s in-house RumbleWallet in a video reposted by the company’s official X page.

A historic first at @LuganoPlanB — @thevivafrei became the first creator tipped through the Rumble Wallet. Freedom meets finance👊 pic.twitter.com/WD0EohedIu

— Rumble 🏴‍☠️ (@rumblevideo) October 24, 2025

The new tipping functionality enables creators to receive Bitcoin payments directly from viewers, expanding the platform’s existing monetization options. Over the past year, Rumble has increasingly developed blockchain integrations, aiming to introduce cryptocurrency tipping across multiple digital assets.

As creators attract global audiences, video platforms are turning to crypto-based payment systems to ensure faster, borderless transactions. Rumble’s move aligns with the growing wave of corporate adoption of cryptocurrencies in the US, which has accelerated since President Trump’s second term began.

On Friday, banking giant JP Morgan,  managing over $4 trillion in assets, announced plans to accept Bitcoin and Ethereum holdings as collateral for institutional loans.

Bitcoin Price Forecast Today: Bears Mount Weekend Resistance at $112,300
Bitcoin price stabilized near $111,600 at press time on Saturday, October 25, recording a 1.5% intraday gain. However, trading activity dropped sharply, with BTC’s 24-hour volume falling 42% to $30.6 billion. The price uptick amid weaker trading volumes suggests that few large-sized buyers likely influenced the mild bounce.

Bitcoin Liquidation Map, October 25, 2025 | Source: Coinglass

Derivatives market data indicates that leverage remains heavily skewed toward bullish positions, with long contracts worth $7.83 billion open in the past week, compared to $5.2 billion in active shorts. Despite this, Coinglass Liquidation Map charts highlight a dense cluster of $920 million short contracts deployed around $112,310, accounting for 17% of total active short leverage positions.

If Bitcoin breaks through this resistance, analysts expect a relatively smooth upward path before encountering the next selling zone near $114,000. However, failure to sustain momentum could trigger liquidations, dragging prices back toward short-term support near $106,500 where bulls anchored $4.5 billion active long contracts.

Disclaimer: Coinspeaker is committed to providing unbiased and transparent reporting. This article aims to deliver accurate and timely information but should not be taken as financial or investment advice. Since market conditions can change rapidly, we encourage you to verify information on your own and consult with a professional before making any decisions based on this content.

Bitcoin News, Cryptocurrency News, News

Ibrahim Ajibade is a seasoned research analyst with a background in supporting various Web3 startups and financial organizations. He earned his undergraduate degree in Economics and is currently studying for a Master’s in Blockchain and Distributed Ledger Technologies at the University of Malta.

Ibrahim Ajibade on LinkedIn

For years, XRP has lived in the shadow of Bitcoin and Ethereum, often labeled the “bankers’ coin” and dismissed by many in traditional finance. Yet, something is changing beneath the surface. The same institutions that once mocked or ignored it are now quietly preparing to embrace it.

When the United States approved spot Bitcoin ETFs earlier this year, some of the loudest voices cheering the decision came from firms that had long been skeptical of crypto. Asset managers that once warned investors away from Bitcoin are now earning fees from it. Many analysts believe the same playbook will soon unfold for XRP.

One analyst said that once companies like BlackRock and Fidelity can profit directly from an XRP product, the tone will shift. The same firms that spent years on the sidelines will begin talking about the advantages of the XRP Ledger: fast settlement, scalability, and low cost. They will frame it as part of the next evolution of digital payments and decentralized finance.

The retail mindset and the numbers behind itThis shift may align with how new investors already think about value. The psychology is simple: people like owning more units of something. The average person compares numbers, not market caps.

As the analyst explained, a retail investor with $1,000 faces a choice — buy one percent of a Bitcoin or 350 XRP. The math shapes the story. Bitcoin’s market cap sits near $2.5 trillion, while XRP hovers around $180 billion. The gap suggests larger room to grow. Whether or not that logic is perfect, it has real influence on how new money flows into the market.

A changing narrative inside Ripple’s worldFor a long time, critics argued that Ripple, the company behind XRP, cared more about its own success than the open-source ledger itself. That narrative is fading.

Ripple’s co-founder and chief technologist, David Schwartz, recently shifted into a new role focused entirely on building decentralized finance applications on the XRP Ledger. The initiative is backed by a $1 billion fund. His move underscores a clear message: development on the ledger, not just corporate adoption, is now a central focus.

That pivot could reshape how the ecosystem grows. Developers are expected to build new DeFi platforms, liquidity tools, and on-chain applications that bring utility back to the token.

Direct buying and a potential supply squeezeThere’s also a new twist in how major players plan to accumulate XRP. Instead of arranging private over-the-counter deals, they’re buying directly from exchanges, the same way retail investors do.

This detail matters. Buying on public markets puts direct pressure on liquidity. More demand chasing the same supply can create what traders call a “supply shock.” If this continues, it could shift the price dynamic in ways not seen before.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

5 minutes ago

Smaller Bitcoin miners surge in hashrate and debt as competition intensifies post-halving, reshaping the industry’s balance of power.

31

The Bitcoin mining industry is becoming increasingly competitive, with so-called tier-2 operators closing the gap on established leaders in realized hashrate — a sign of a more level playing field following the 2024 halving.

According to The Miner Mag, companies such as Cipher Mining, Bitdeer and HIVE Digital have rapidly expanded their realized hashrate after several years of infrastructure growth, narrowing the distance to top players like MARA Holdings, CleanSpark and Cango.

“Their ascent highlights how the middle tier of public miners — once trailing far behind — has rapidly scaled production since the 2024 halving,” The Miner Mag wrote in its latest Miner Weekly newsletter. 

While MARA, CleanSpark and Cango maintained their positions as the three largest public miners, rivals including IREN, Cipher, Bitdeer and HIVE Digital posted significant year-over-year increases in realized hashrate.

In total, the top public miners reached 326 exahashes per second (EH/s) of realized hashrate in September, more than double the level recorded a year earlier. Collectively, they now account for nearly one-third of Bitcoin’s total network hashrate.

Year-over-year growth in realized hashrate. Source: The Miner MagHashrate represents the total computational power miners contribute to securing the Bitcoin blockchain. Realized hashrate, however, measures actual onchain performance, or the rate at which valid blocks are successfully mined.

For publicly traded miners, it also serves as a closer indicator of operational efficiency and revenue potential, making it a key metric ahead of third-quarter earnings season.

Bitcoin miners ramp up hash warsIn the race for market share, Bitcoin mining companies are taking on record levels of debt as they expand into new mining rigs, artificial intelligence infrastructure and other capital-intensive ventures.

Total debt across the sector has surged to $12.7 billion, up from $2.1 billion just 12 months ago, according to research by VanEck. The researchers noted that miners must continuously invest in next-generation hardware to maintain their share of Bitcoin’s total hashrate and avoid falling behind competitors.

The growing debt of Bitcoin miners. Source: VanEckSome mining companies have turned to AI and high-performance computing workloads to diversify revenue streams and offset declining margins following the 2024 Bitcoin (BTC) halving, which reduced block rewards to 3.125 BTC.

HBAR Foundation just expanded Hedera's staking reward vault with a $42 million deposit: will the price react accordingly?

Bitcoin price struggled to establish a stable direction in the past week, as intense levels of volatility continue to rock the market. Following two weeks of market correction, the premier cryptocurrency attempted a price rebound, reaching around $112,000 before retracing to $107,000 price zone. 

Presently, Bitcoin trades in the $111,000 price range after some steady gains in the past 48 hours. Interestingly, a popular analyst with the X username DaanCrypto has identified an insightful trend amidst this market uncertainty.

Sideways Bitcoin Market Sets Stage For Explosive Move As Liquidity Builds
In a post on Friday, DaanCrypto shared an important on-chain development of the Bitcoin market following the highly volatile price moves in October 2025.  Despite the consistent price swings, the analyst explains that BTC has remained locked in a local price range over the past two weeks,  with its present price hovering above the midpoint of this structure.

This sideways action has been driven by buyers and sellers repeatedly foiling each other’s attempts to break out, thereby preventing the asset from establishing a decisive breakout pattern. Amid the continuous consolidation, untriggered liquidation levels are accumulating just above and below the local price range.

Source: @DaanCrypto on X
This pattern is typical of Bitcoin’s pre-breakout phases. DaanCrypto explains that the longer the price consolidates within a tight corridor, the more liquidity pools build up outside it. Notably, when price eventually sweeps these clusters, it often triggers a cascade of liquidations and stop orders, which fuel the next large price move. 

Using data from Coinglass, DaanCrypto has identified $106,000 as a level with the heaviest concentration of long liquidations. Therefore, this price point functions as a critical support zone, and a downward wick below which could trigger selling forces pushing Bitcoin to deeper levels. 

Meanwhile, the $115,000 region holds a thick short-side liquidity, meaning a push above this threshold could fuel a rapid short squeeze and propel BTC to higher levels, perhaps beyond its current all-time high at $126,210.

Bitcoin Still On For A Comeback? 
In contrast to popular sentiments of an “Uptober” and blooming Q4, Bitcoin has failed to achieve a sustainable price growth in October. A report from the Bitcoin Archive states that the crypto asset’s return in Q4 2025 is now estimated at -2.84%. This figure shows an extreme underperformance as Bitcoin’s average Q4 is valued at 74.77%.  

However, with over 60 days remaining until the end of 2025, there is still ample time for the premier cryptocurrency to pull off a market recovery. After the CPI data met expectations, the chances of an interest rate cut have increased, and an eventual announcement by the Federal Reserve could perhaps trigger Bitcoin’s rebound, among other factors.

At press time, Bitcoin continues to trade at $111,424, reflecting a 3.91% gain in the past seven days.

BTC trading at $111,493 on the daily chart | Source: BTCUSDT chart on Tradingview.com
 Featured image from iStock, chart from Tradingview

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACR25--BMS Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR.

Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented Biomarker data informing use of investigational CAR-T cell therapy rapcabtagene autoleucel (YTB323) in systemic lupus erythematosus also to be presentedData underscore Novartis commitment to advance innovative medicines for complex, difficult-to-treat autoimmune diseases with high unmet needNovartis to hold virtual investor event following ACR highlighting immunology pipeline progress Basel, October 25, 2025 – Novartis announced today plans to present data from 27 company- or investigator-sponsored abstracts across its Immunology portfolio and pipeline at the 2025 American College of Rheumatology (ACR) Convergence. Data to be presented include late-breaking pivotal Phase III results from the replicate NEPTUNUS-1 and NEPTUNUS-2 trials evaluating ianalumab in Sjögren’s disease1. New biomarker data from an ongoing Phase 1/2 study of rapcabtagene autoleucel in severe refractory systemic lupus erythematosus will also be presented, along with Cosentyx data in multiple rheumatology indications2,3.

“Our data at this year’s ACR demonstrate that Novartis is at the forefront of scientific innovation and is developing medicines for some of the most challenging autoimmune diseases, such as Sjögren’s,” said Angelika Jahreis, Global Head, Development, Immunology, Novartis. “Autoimmune diseases are often devastating and life-limiting. We are committed to developing new therapies with the potential to transform the standard of care for the millions who continue to suffer from rheumatic diseases.”

Ianalumab is an investigational medicine that has the potential to become the first targeted therapy for Sjögren’s disease, an area of high unmet need with no FDA-approved treatments4,5. Sjögren’s disease affects millions of people globally and is the second most prevalent rheumatic disease6.

Additional presentations include data for rapcabtagene autoleucel, a novel one-time investigational CAR-T cell therapy being evaluated across several refractory autoimmune disease for its potential to induce an immune reset7-9. Further presentations will feature real-world data on Cosentyx® (secukinumab) in psoriatic arthritis, and new insights into the dual mode of action of ianalumab.

Investor call on Novartis Immunology pipeline 
Following the conclusion of ACR, Novartis will host a conference call for investors to provide updates on the company’s Immunology pipeline on Thursday, October 30, 2025, at 11:30 a.m. ET. Details can be found here.

Key abstracts accepted by ACR include:

Molecule/disease state Abstract title Abstract number/ presentation details      Ianalumab Sjögren’s disease Ianalumab demonstrates significant reduction in disease activity in patients with Sjögren’s Disease: Efficacy and safety results from two global Phase 3, randomized, placebo-controlled double-blind studies (NEPTUNUS-1 and NEPTUNUS-2)  Abstract #LB24
Oral presentation
Oct. 29, 9:15 am – 9:30 am CST Sjögren’s disease Evaluation of the dual mode of action of Ianalumab (VAY736) in the circulation and salivary gland tissue of patients with Sjögren’s Disease: Results from a Phase 2 mechanistic study Abstract #2296
Poster presentation
Oct. 28, 10:30 am – 12:30 pm CST Sjögren’s disease Ianalumab’s dual mode of action: targeting B cells through enhanced B cell depletion and blockade of B cell activating factor receptor signaling Abstract #0903
Poster presentation
Oct. 27, 10:30 am – 12:30 pm CST Systemic lupus erythematosus Achieving sustained lupus low disease activity state and remission with ianalumab (VAY736) in patients with systemic lupus erythematosus: A post hoc analysis from a phase II study Abstract #0801
Oral presentation
Oct. 26, 1:00 pm – 1:15pm CST Rapcabtagene autoleucel Systemic lupus erythematosus Biomarker data from an open-label, Phase 1/2 Study for YTB323 (Rapcabtagene Autoleucel, a rapidly manufactured CD19 CAR-T therapy) suggest reset of the B Cell compartment in severe refractory SLE Abstract #2696
Oral Presentation
Oct. 29, 12:15pm – 12:30 pm CST Cosentyx (secukinumab) Psoriatic arthritis Comparison of incidence of psoriatic arthritis in patients with psoriasis treated with interleukin-17 inhibitors vs interleukin-23 inhibitors, interleukin-12/23 inhibitors, and tumor necrosis factor inhibitors in real-world practice: a retrospective study  Abstract #2689
Oct. 29, 12:15pm – 12:30 pm CST About Novartis Immunology 
At Novartis, we’re advancing bold science for autoimmune diseases, where meaningful therapeutic progress has long stalled.

With a growing legacy of first-in-class innovation across Rheumatology, Dermatology and Allergy, and a diverse industry-leading pipeline, we’re committed to shaping what’s next in Immunology. From small molecules to biologics and CAR-T cell therapy, our innovation is powered by cutting-edge science, focused on where we can have the greatest impact on patient outcomes and supported by strong collaboration across the healthcare ecosystem.

We’re not just treating autoimmune diseases. We’re reimagining medicine, together.

Product information
For full prescribing information, including approved indications and important safety information about marketed products, please visit https://www.novartis.com/about/products

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis 
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

References

Novartis. Data on file.Morand E, et al. Biomarker Data From an Open-Label, Phase 1/2 Study for YTB323 (Rapcabtagene Autoleucel, a Rapidly Manufactured CD19 CAR-T Therapy) Suggest Reset of the B Cell Compartment in Severe Refractory SLE. Abstract presented at ACR Convergence 2025. Accessed September 19, 2025. https://acrabstracts.org/abstract/biomarker-data-from-an-open-label-phase-1-2-study-for-ytb323-rapcabtagene-autoleucel-a-rapidly-manufactured-cd19-car-t-therapy-suggest-reset-of-the-b-cell-compartment-in-severe-refractory-sle/Armstrong A, et al. Comparison of Incidence of Psoriatic Arthritis in Patients With Psoriasis Treated With Interleukin-17 Inhibitors vs Interleukin-23 Inhibitors, Interleukin-12/23 Inhibitors, and Tumor Necrosis Factor Inhibitors in Real-World Practice: A Retrospective Study. Abstract presented at ACR Convergence 2025. Accessed September 19, 2025. https://acrabstracts.org/abstract/comparison-of-incidence-of-psoriatic-arthritis-in-patients-with-psoriasis-treated-with-interleukin-17-inhibitors-vs-interleukin-23-inhibitors-interleukin-12-23-inhibitors-and-tumor-necrosis-factor-i/Dorner T, et al. Safety and Efficacy of ianalumab in patients with Sjogren’s disease: 52-week results from a randomized, placebo-controlled, phase 2b dose-ranging study. Arthritis and Rheumatology. 2025; 77(5):560-570 Negrini S, et al. Sjogren’s syndrome: a systemic autoimmune disease, Clin Exp Med. 2022; 22(1): 9-25 National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Care Services; Committee on Selected Immune Disorders and Disability. Sjogren’s Disease/Syndrome. Accessed September 11, 2025. https://www.ncbi.nlm.nih.gov/books/NBK584486/  ClinicalTrials.gov NCT05798117 [Last accessed: September 2025] ClinicalTrials.gov NCT06665256 [Last accessed: September 2025] ClinicalTrials.gov NCT06655896 [Last accessed: September 2025] # # #

October 25, 2025 11:01 ET

 | Source:

Cullinan Therapeutics, Inc.

CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases

CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, will present new preclinical data for CLN-978, its novel investigational CD19xCD3 bispecific T cell engager. These data will be presented at the American College of Rheumatology (ACR) Convergence 2025, being held in Chicago, Illinois, October 24-29, in a poster presentation session on October 28, 10:30 a.m.-12:30 p.m. CT (Poster Session C, Poster Number 2293). Cullinan will also have a Booth (#1074) in the Exhibit Hall.

New in vitro preclinical data show CLN-978 robustly and specifically depleted target B cells while activating T cells in human peripheral blood mononuclear cells (PBMC) derived from patients with rheumatoid arthritis (RA), Sjögren's disease (SjD), or systemic lupus erythematosus (SLE). These effects were similar to those observed with PBMCs from healthy donors.

Dose-dependent B cell depletion was observed following subcutaneous administration of CLN-978 in nonhuman primates (NHPs). Doses of CLN-978 considered well tolerated in the NHPs achieved deep and sustained B cell depletion in blood and multiple tissues including bone marrow and lymph nodes, suggesting the potential to achieve meaningful B cell depletion in patients.

In a murine model of SLE, CLN-978 treatment led to a reduction in circulating B cells, levels of anti-dsDNA IgG, and IgG deposition in the kidney, indicating a disease-modifying effect in both peripheral blood and affected disease tissues.

“We continue to generate preclinical data that reinforce the potential of CLN-978 as a highly potent T cell engager designed to deplete B cells deeply across multiple autoimmune diseases,” said Jeffrey Jones, MD, MBA, Chief Medical Officer, Cullinan Therapeutics. “In parallel, we are advancing our global clinical programs in rheumatoid arthritis, Sjögren’s disease, and systemic lupus erythematosus, recognizing the significant unmet needs for people living with these diseases. Current therapies are typically limited to addressing disease symptoms whereas CLN-978 has the potential to modify the underlying pathophysiology of the disease itself.”

Cullinan is advancing the global clinical development of CLN-978 through its OUTRACE studies across RA (NCT06994143), SjD (NCT07041099), and SLE (NCT06613360), with active trials now underway across all three indications and in multiple countries.

About CLN-978
CLN-978 is a novel, differentiated and highly potent CD19xCD3 bispecific T cell engager. CLN-978 triggers redirected lysis of CD19-expressing target cells in vitro and in vivo. CLN-978 is engineered to achieve very high affinity binding to CD19 to efficiently target B cells, including those with very low CD19 levels. Small in molecular size (65 kDa), CLN-978 contains two single-chain variable fragments, one binding with very high affinity to the CD19 target and the other binding to CD3 on T cells, and a single-domain antibody binding to human serum albumin to extend serum half-life. CLN-978 was developed by an internal Cullinan team and is a wholly owned asset. CLN-978 has the potential to offer a convenient, off-the-shelf, subcutaneously delivered therapeutic option for patients living with autoimmune diseases and is being studied in Cullinan’s OUTRACE studies for patients with rheumatoid arthritis, Sjögren’s disease, and systemic lupus erythematosus. CLN-978 is investigational and has not been approved by any health authority.

About Cullinan Therapeutics   
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X. 

Forward Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding the company’s beliefs and expectations regarding: future data presentations, our preclinical and clinical developments plans and timelines for CLN-978, the clinical and therapeutic potential of CLN-978, and other statements that are not historical facts. The words “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “potential,” “project,” “pursue,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of regulatory submissions; the risk that any INDs or other global regulatory submissions we may file with the United States Food and Drug Administration or other global regulatory agencies are not cleared on our expected timelines, or at all; the success of our clinical trials and preclinical studies; the risks related to our ability to protect and maintain our intellectual property position; the risks related to manufacturing, supply, and distribution of our product candidates; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; and the success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither the company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made.

Contacts:

Investors
Nick Smith
+1 401.241.3516
[email protected]

Media
Rose Weldon
+1 215.801.7644
[email protected]

Pinnacle Silver & Gold Corp (TSX-V:PINN, OTCQB:NRGOF) CEO Robert Archer talked with Proactive about the company’s recent strategic shift, including its new project in Mexico and key personnel hires to support its development.

The project, El Potrero, was acquired at the end of February and marks a renewed focus for the company. Archer explained that the business model reflects his past work at Great Panther, with the objective to rapidly restart past-producing mines and build the company through operational cash flow, rather than relying on equity markets.

Archer described El Potrero as a previously producing asset that was active in the late 1980s, with no modern exploration since the 1990s. “We think there's a lot of potential there,” he said, adding that remnants of an existing plant offer an opportunity for a faster restart.

To advance the project, Pinnacle has brought back two experienced team members: Carlos, who will lead operations, and Jorge, on the exploration side—both of whom worked with Archer at the Guanajuato mine. Archer said, “Carlos has worked for me a couple of times... I think I can honestly say he was the best mine manager that we ever had.”

The next steps include finalising mine planning and assessing the plant rebuild, with more than 1,000 samples already collected over the past eight months.

Netflix Inc (NASDAQ: NFLX) tanked below its 200-day moving average this week – triggering concerns among technical traders. But widely followed investor, Josh Brown, remains constructive on the streamer for the long-term.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of WFC.PR.Z either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I also have a long position in WFC.PR.L.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

-

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of MidWestOne Financial Group, Inc. (NasdaqGS: MOFG) to Nicolet Bankshares, Inc. (NYSE: NIC). Under the terms of the proposed transaction, shareholders of MidWestOne will receive 2.6 shares of Farmers common stock for each share of MidWestOne that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-mofg/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

More News From Kahn Swick & Foti, LLC

Back to Newsroom

Intel (INTC) stock pulls back during intraday trading on Friday, erasing initial gains following the legacy chipmaker's earnings report. Bernstein managing director and senior analyst Stacy Rasgon, who lifted his price target on the stock but maintained his market performance rating, explains why Intel shares reversed direction after releasing quarterly results.

Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolismRobust monotherapy activity, as well as combination activity with BBOT’s KRASG12C ON/OFF inhibitor, BBO-8520, and panKRAS inhibitor, BBO-11818, was observed at well-tolerated dose levels in a panel of KRAS-mutant modelsThe combination of a KRAS inhibitor with a PI3Kα pathway inhibitor may maximize the response rate and reduce the development of adaptive resistance mechanisms due to full inhibition of both MAPK and PI3Kα signalingBBOT-10203 is currently being evaluated in the Phase 1 BREAKER-101 trial for patients with HER2+ amplified or HR+/HER2- breast cancer, and KRAS mutant colorectal or non-small cell lung cancer with initial Phase 1 clinical data expected in the first half of 2026 SOUTH SAN FRANCISCO, Calif., Oct. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced new preclinical data showing BBO-10203 selectively and specifically blocks the physical interaction between RAS and PI3Kα, resulting in the inhibition of RAS-driven PI3Kα-AKT signaling in tumors without the risk of hyperglycemia. In addition, combination activity with BBOT’s KRASG12C ON/OFF inhibitor, BBO-8520, and panKRAS inhibitor, BBO-11818, was observed at well tolerated dose levels in a panel of KRAS mutant models. The data were presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

“Aberrant activation of the PI3Kα pathway is among the most common oncogenic drivers across human cancers and leads to promotion of tumor growth, survival, and resistance to standard therapies,” said Pedro Beltran, PhD, Chief Scientific Officer of BBOT. “Current PI3Kα inhibitors are hindered by dose-limiting toxicities like hyperglycemia, which restrict target coverage, limit the number of eligible patients, and shorten the duration of treatment – leaving a significant unmet medical need. We’ve designed BBO-10203 to break the interaction between RAS and PI3Kα and inhibit RAS-mediated activation of the PI3Kα pathway. These preclinical data demonstrate BBO-10203 can accomplish this in in vivo studies without affecting glucose metabolism and achieve robust anti-tumor activity both as a monotherapy and in combination with our KRAS inhibitors, BBO-8520 and BBO-11818.”

These preclinical findings demonstrate BBO-10203 covalently binds PI3Kα on cysteine 242 in the RAS binding domain, breaking the protein-protein interaction between RAS and PI3Kα. Monotherapy results show achievement of complete cellular target engagement at low nanomolar concentrations and oral bioavailability with robust dose- and time-dependent inhibition of pAKT across diverse human cancer cell lines with KRAS mutations. Importantly, BBO-10203 does not induce hyperglycemia or hyperinsulinemia during an oral glucose tolerance test. In a panel of cell-line derived xenograft (CDX), patient-derived xenograft (PDX), and genetically engineered mouse (GEM) models, treatment with BBO-10203, both as a monotherapy and in combination with BBO-8520, BBOT’s direct inhibitor of KRASG12C in both the ON and OFF states, and with BBO-11818, the company’s panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants, show robust anti-tumor activity. Importantly, the combination of BBO-10203 + BBO-8520 and BBO-10203 + BBO-11818 induces deep tumor regressions through direct effects on tumor cell proliferation and apoptosis and are well-tolerated.

BBO-10203 is currently being evaluated in the Phase 1 BREAKER-101 trial for patients with HER2+ amplified or HR+/HER2- breast cancer, and KRAS mutant colorectal or non-small cell lung cancer as a monotherapy and in combination with standard of care treatment, and will be evaluated in combination with KRAS inhibitors.

“We are pleased to share these preclinical data on BBO-10203’s potential as a RAS:PI3Kα breaker,” said Eli Wallace, PhD, Chief Executive Officer of BBOT. “By breaking the interaction between RAS and PI3Kα while preserving normal insulin signaling, these results further support our belief that BBO-10203 represents a truly differentiated approach with significant biological and therapeutic potential. We continue to enroll patients in our Phase 1 BREAKER-101 trial and look forward to expanding into combination studies, including with our own KRAS inhibitors.”

A copy of the poster titled “BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia” will be available on the “Publications” page of the BBOT website following the conference.

About BBO-10203
BBO-10203 is a first-in-class small molecule which breaks the protein-protein interaction between RAS and PI3Kα and inhibits RAS-mediated activation of the PI3Kα pathway. It selectively disrupts oncogenic RAS-PI3Kα signaling while sparing insulin-mediated glucose uptake, potentially maintaining efficacy with reduced risk of hyperglycemia or hyperinsulinemia. BBO-10203 is currently being evaluated in the Phase 1 BREAKER-101 trial for patients with locally advanced or metastatic HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer. Initial Phase 1 clinical data are expected in the first half of 2026.

About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements in this press release that are not historical facts may be deemed forward-looking statements,  which generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends. These statements are based on various assumptions, whether or not identified in this press release, and are the current expectations of BBOT’s management and are not predictions of actual performance. Many actual events and circumstances are beyond the control of BBOT. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks relating to the uncertainty of the projected financial information with respect to BBOT; risks related to the approval of BBOT’s product candidates and the timing of expected regulatory and business milestones, including the progress of enrollment in clinical trials and availability of data from ongoing and planned clinical trials; the impact of competitive products; risks relating to BBOT’s ability to obtain sufficient supply of materials; and those factors discussed in documents BBOT has filed or will file with the U.S. Securities and Exchange Commission.

In addition, forward-looking statements reflect BBOT’s expectations, plans, or forecasts of future events and views as of the date of this press release and are qualified in their entirety by reference to the cautionary statements herein. BBOT anticipates that subsequent events and developments will cause BBOT’s assessments to change. These forward-looking statements should not be relied upon as any guarantee, assurance, prediction or definitive statement of fact or probability or as representing BBOT’s assessments as of any date subsequent to the date of this press release. Neither BBOT, nor any of its affiliates undertake any obligation to update these forward-looking statements, except as required by law.

BBOT Contacts:

Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
[email protected]

Media Contact:
Jake Robison
Inizio Evoke Comms
[email protected]

NEW YORK, Oct. 25, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”), of the important November 18, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Jasper Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (2) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of Jasper’s products, including briquilimab; (3) the foregoing increased the likelihood of disruptive cost-reduction measures; (4) accordingly, Jasper’s business and/or financial prospects, as well as briquilimab’s clinical and/or commercial prospects, were overstated; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Jasper Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Netflix (NASDAQ: NFLX) shares have entered dangerous technical territory, flashing multiple bearish signals that suggest momentum could unravel further. 

The stock closed at $1,094, slipping below all its major moving averages, the 20-day, 50-day, 100-day, and 200-day, in a sharp move that often precedes extended downside pressure.

Notably, the stock has had a rough couple of sessions, dropping almost 10% in the past week. Still, it remains up 23% year-to-date. 

Netflix stock price analysis chart. Source: Barchart
This marks the first time since the streaming giant’s long-term uptrend began that Netflix has decisively fallen below its 200-day simple moving average (SMA) of $ 1,114.33. The last such breach saw shares trading under $350.

Netflix stock price analysis chart. Source: TrendSpider
Additionally, momentum indicators are flashing warnings. The RSI sits just above oversold levels, signaling accelerating bearish momentum despite signs of short-term exhaustion. 

While similar readings have previously led to brief stabilization, the current setup appears far weaker. 

Rising selling volume near support suggests institutions may be trimming exposure after months of consolidation. With Netflix now trading below all major trendlines, bulls must quickly reclaim the 200-day moving average or risk a deeper correction.

Why Netflix is falling 
The latest bearish sentiment toward Netflix comes despite upbeat revenue and earnings guidance, as investors focused on a weaker-than-expected operating margin and renewed valuation concerns. 

In the most recent quarter, the streaming entity posted a 28% operating margin, below its 31.5% forecast, due to an unexpected tax expense in Brazil. Although Netflix said the issue won’t affect future results, it trimmed its 2025 margin outlook to 29% from 30%.

At the same time, the stock has faced uncertainty amid rising competition from AI-driven content platforms and renewed backlash after Elon Musk urged users to cancel subscriptions over “woke” content. 

Despite strong ad sales and hit titles, investors remain cautious about Netflix’s profitability and valuation heading into 2025.

Featured image via Shutterstock

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Oct 25, 2025 at 14:23 // Price

Sui's price has resumed its decline after rising above the $2.48 support. SUI price analysis by Coinidol.com.

SUI price long-term prediction: bearish

The cryptocurrency has already fallen to a low of $2.00, but the bulls bought the dips. The upward correction was short-lived, ending at a high of $3.01. Yesterday, SUI fell to a low of $2.28 and began moving sideways.

On the downside, if the bears breach the $2.30 support level, SUI will revert to its previous low of $2.00. If the current support holds, SUI will be forced to trade in a range above $2.30. SUI may then rise and retest the $3.00 barrier. At the time of writing, SUI is trading at $2.49.

Technical indicators

Key supply zones: $4.00, $4.20,$4.40

Key demand zones: $3.00, $2.80, $2.60 

SUI price indicator analysis

The moving average lines are trending downward, and the 21-day SMA is below the 50-day SMA, indicating a downtrend. On the 4-hour chart, the moving average lines are horizontal, indicating a sideways trend. Doji candlesticks dominate the price action, keeping the altcoin in a range.

SUI/USD daily chart - September 24, 2025

What is the next move for Sui?

SUI continues to move sideways, above the $2.30 support but below the $3.00 resistance. The moving average lines have impeded the price's upward movement. The cryptocurrency price remains locked below the moving average lines. Doji candlesticks dominate the altcoin market, signalling that traders are uncertain about its direction.

SUI/USD 4-hour chart - September 24, 2025

Disclaimer. This analysis and forecast are the personal opinions of the author. The data provided is collected by the author and is not sponsored by any company or token developer. This is not a recommendation to buy or sell cryptocurrency and should not be viewed as an endorsement by Coinidol.com. Readers should do their research before investing in funds. 

Ethereum’s rebound setup strengthens as whale wallets add roughly $588 million in ETH over 24 hours.Dormant coin movement falls 88%, hinting that holders are staying put and conviction is growing.Key resistance levels at $3,986 and $4,281 remain crucial for confirming a full Ethereum price reversal and sustained rally.Ethereum (ETH) is once again teasing a turnaround. Over the past month, the Ethereum price has slipped about 1.9%, but the past seven days show a mild 2.1% rebound, as traders attempt to recover lost ground.

Still, the broader tone remains slightly negative. Previous bounces failed to extend into full rallies, repeatedly capped at key technical levels. Now, with on-chain data shifting again, another rebound is forming — and this one looks more convincing.

Sponsored

Whales Add While Dormant Holders RiseThe Spent Coins Age Band, a metric that tracks how much ETH moves across wallets of all ages, has dropped from 346,000 ETH on October 22 to just 42,100 ETH on October 25 — an 88% decline in movement.

That means coins are staying put rather than circulating — a strong signal that dormant holdings are rising and holders are showing renewed conviction. Both short and long-term investors appear to be waiting for higher prices before rotating their assets.

Fewer ETH Moving: SantimentWant more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.

Spent Coins Age Band shows total ETH moved across age bands. When it drops, fewer coins are leaving wallets, signaling higher dormancy — often a bullish sign.

Sponsored

At the same time, whale addresses holding more than 10,000 ETH have increased their combined holdings. Over the past 24 hours, they have raised their stash from 100.41 million to 100.56 million ETH. That’s a net gain of 150,000 ETH, worth around $588 million at current ETH prices.

Ethereum Whales Back To Buying: SantimentThis mix of rising dormancy and fresh whale accumulation creates a stronger base for Ethereum. Historically, when large holders buy while fewer coins move on-chain, the price tends to stabilize and prepare for the next major leg upward.

One Indicator Holds Ethereum’s Reversal Theory IntactThe Relative Strength Index (RSI) — an indicator that measures the balance between buying and selling pressure — continues to flash signs that Ethereum’s downtrend may be losing strength.

Sponsored

Between September 25 and October 22, the RSI made higher lows while the price made lower lows, forming a bullish divergence that often signals a potential reversal. Similar divergences appeared on October 10 and October 17, both of which led to short-lived bounces.

Ethereum Reversal Theory Still Intact: TradingViewThis time, however, the supporting on-chain data looks stronger, suggesting the setup could finally evolve into something larger.

Sponsored

Fibonacci Still Defines The Ethereum Price Reversal PathDespite improving technicals, the Ethereum price remains trapped below critical resistance zones that have repeatedly capped every bounce. The 0.382 Fibonacci level at $3,986 and the 0.618 level at $4,281 have rejected two rally attempts in a row — including those on October 10 and October 17.

To confirm real strength, ETH needs a daily close above $4,281, roughly 9% above current levels. That would mark the first clear shift in market control, possibly setting the stage for targets at $4,491 and $4,954.

Ethereum Price Analysis: TradingViewIf the breakout fails and ETH slips below $3,804, a deeper pullback toward $3,509 could follow. For now, though, the setup looks cleaner than before — whale accumulation, rising dormancy, and a well-defined technical ceiling.

Ethereum’s rebound isn’t guaranteed, but this time, the groundwork beneath it looks stronger than ever.

Disclaimer

In line with the Trust Project guidelines, this price analysis article is for informational purposes only and should not be considered financial or investment advice. BeInCrypto is committed to accurate, unbiased reporting, but market conditions are subject to change without notice. Always conduct your own research and consult with a professional before making any financial decisions. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.